Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Research & Discovery » Proteomics & Protein Research » Study Says Ciphergen s New Ovarian Cancer Test Scores Well For Both Sensitivity, Specificity

Study Says Ciphergen s New Ovarian Cancer Test Scores Well For Both Sensitivity, Specificity

Nov 05, 2004
Premium

In an ongoing study to validate biomarkers for ovarian cancer, scientists collaborating with Ciphergen showed that when three newly discovered biomarkers were combined with a standard biomarker called CA 125, the test scored between .88 and .91 out of a perfect score of one, in terms of specificity and sensitivity.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

Same Old Error

The Washington Post reports that the CDC's SARS-CoV-2 test issues reflect earlier ones it had with Zika virus testing.

Own Merits

NPR writes that even with thousands of new COVID-19 papers, each should be evaluated based on its own quality.

Back to Neanderthals

Researchers traced a gene cluster linked to COVID-19 severity to Neanderthals, the New York Times reports.

PNAS Papers on Small Molecule From Soil Bacteria, Circulating Tumor Cell Chip, More

In PNAS this week: soil bacteria-derived small molecules affect centrosomal protein, microfluidics approach for capturing circulating tumor cells, and more.

What's Popular?

In Proteomics & Protein Research

  1. NIH Using Fluidigm Mass Cytometry, Other Omics Technologies to Profile COVID-19 Patients

    Premium

  2. Cancer Research UK, Abcam Partner to Develop Custom Antibodies for Cancer Research

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.